Axios Alerts: Novavax says COVID vaccine was 90% effective in key trial, including against variants

Alerts   Axios    Novavax says COVID-19 vaccine was 90% effective in Phase 3 trial Why it matters: The results of the late-stage clinical trial could pave the way for the FDA to clear a 4th COVID-19 vaccine for emergency use by the end of the year.   Download the Axios App Follow Axios on Social Media Contact Axios, 3100 Clarendon B‌lvd, Suite 1300, Arlington VA 22201   You received this email because you signed up for news alerts from Axios. Change your preferences or unsubscribe here.